Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration in Patients With Type 1 Diabetes Mellitus.

Next Previous
Search
Trial Profile

A Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration in Patients With Type 1 Diabetes Mellitus.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Nov 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs C-peptide (Primary)
  • Indications Diabetic neuropathies; Type 1 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 05 Oct 2012 Results from the phase Ib part of the study which assessed tolerability and pharmacokinetics presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
  • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 12 Jun 2012 Pharmacokinetics results of the 30 patient phase Ib portion of this trial presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top